TALPHERA
Talphera is a specialty pharmaceutical company developing and commercializing therapies in medically supervised settings. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute postoperative pain in hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures.
TALPHERA
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.talphera.com
Total Employee:
11+
Status:
Active
Contact:
650-216-6500
Email Addresses:
[email protected]
Total Funding:
191.65 M USD
Technology used in webpage:
Domain Not Resolving IPv6
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-11-15 | Lowell Therapeutics | Lowell Therapeutics acquired by Talphera | N/A |
| 2020-03-16 | Tetraphase Pharmaceuticals | Tetraphase Pharmaceuticals acquired by Talphera | N/A |
Investors List
Nantahala Capital Management
Nantahala Capital Management investment in Post-IPO Equity - Talphera
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Talphera
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Talphera
Skyline Ventures
Skyline Ventures investment in Post-IPO Debt - Talphera
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-09-30 | Encycle Therapeutics | Talphera investment in Venture Round - Encycle Therapeutics | 2.85 M CAD |
Newest Events participated
Official Site Inspections
http://www.talphera.com Semrush global rank: 5 M Semrush visits lastest month: 1.66 K
- Host name: acelrx.tempurl.host
- IP address: 149.28.220.224
- Location: Matawan United States
- Latitude: 40.4652
- Longitude: -74.2307
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07747
More informations about "Talphera"
Optimizing outcomes in medically supervised settings
At Talphera, we are focused on the development and commercialization of innovative therapies for use in medically supervised settings. Grounded in the understanding that patient outcomes depend on the quality of the tools …See details»
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Jan 9, 2024 Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine …See details»
Talphera - Crunchbase Company Profile & Funding
Talphera is a specialty pharmaceutical company developing and commercializing therapies in medically supervised settings. It offers NanoTab, a tablet for oral transmucosal administration. …See details»
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Jan 9, 2024 The name Talphera was derived from "Talisman", meaning a strong leader, and reflects the new "pharmaceutical era" for the Company. The company's new mission at …See details»
Talphera, Inc. - AnnualReports.com
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s …See details»
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and …See details»
Talphera, Inc. (TLPH) Company Profile & Facts - Yahoo Finance
See the company profile for Talphera, Inc. (TLPH) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
AcelRx becomes Talphera, adopting new name to reflect pain pivot
Jan 10, 2024 Talphera ended September with $13.4 million and warned investors it expected to “need additional capital to fund our planned operations” within 12 months of its filing.See details»
Talphera Inc, TLPH:NMQ profile - FT.com - Financial Times
Nov 1, 2024 Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies …See details»
Talphera Announces Third Quarter 2024 Financial Results and …
Nov 13, 2024 Talphera's registrational study of Niyad™ is named the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) …See details»
Talphera Announces Second Quarter 2024 Financial Results and
Aug 15, 2024 SAN MATEO, Calif., Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical company focused on the development and …See details»
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Jan 9, 2024 Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings. Talphera …See details»
Talphera Announces Third Quarter 2024 Financial Results and …
SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of …See details»
Talphera Announces $26 Million Capital Commitment Through a …
Jan 18, 2024 Talphera's estimate of its cash as of December 31, 2023 is based on management's preliminary, unaudited analysis of Talphera's financial results as of and for year …See details»
Talphera Announces Third Quarter 2024 Financial Results and …
Nov 13, 2024 Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in …See details»
Talphera Announces Third Quarter 2024 Financial Results and
Nov 13, 2024 --Talphera, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised …See details»
Talphera to Host Third Quarter 2024 Financial Results and …
Nov 6, 2024 Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in …See details»
Talphera
5 days ago Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product …See details»
Talphera, Inc. (TLPH) Stock Price, News, Quote & History - Yahoo …
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product …See details»
Our scientific research and publications | Talphera
Explore Talphera’s scientific research about DSUVIA®, sufentanil sublingual tablet, intended to treat acute pain in medically supervised settingsSee details»